Beating the CalendarWide moat

The central, never-ending task of a pharmaceutical company is a race against the calendar: to invent and approve new patented drugs faster than its existing patents expire. This is the meta-capability beneath all the others — the ability to keep the patent estate refilled, to launch tomorrow's blockbusters before today's fall off their cliffs, and thereby to grow rather than wither as the inexorable clock runs on each drug. A company that beats the calendar thrives across generations of drugs; one that falls behind it declines.

Lilly, at present, is beating the calendar decisively. Its current wave of new drugs — the incretins, the Alzheimer's treatment, a deep pipeline behind them — is arriving faster and larger than its older patents are expiring, which is exactly why the company is growing so explosively. The measure of a great drugmaker is not any single drug but this sustained ability to out-run its own expirations, and Lilly's recent record on that score is as strong as any in the industry.

The rub is that beating the calendar is a race that never ends and can be lost. Today's triumphant refilling of the patent estate says nothing certain about the 2030s and beyond, when the incretin patents themselves will expire and the pipeline must produce their replacements. Every pharmaceutical company's history is a cycle of winning and losing this race — growth on the back of new drugs, followed by cliffs when they expire, followed by renewal or decline. Lilly is winning now, impressively; but an owner should understand that beating the calendar is a permanent obligation, not a permanent state — the current lap is orforglipron and retatrutide¹ — and the race must be won again and again forever.